Discover the top 25 companies transforming the autoinjectors market, including Becton, Dickinson and Company (BD), Ypsomed AG, SHL Medical AG, and other industry leaders. Backed by a market projected to grow from $127.30B to $300.46B by 2031 at a CAGR of 18.7%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Autoinjectors Companies

Becton, Dickinson and Company (BD)

Becton, Dickinson and Company (BD) is a global leader in medical technology, specifically recognized for its BD Medical-Pharmaceutical Systems division, which stands as the world’s largest syringe manufacturer. The company provides a comprehensive portfolio of self-injection solutions, including the BD Physioject and BD Intevia disposable autoinjectors, alongside wearable injectors and safety shielding systems. BD’s expertise in drug-device integration and its extensive global manufacturing network make it a critical partner for pharmaceutical companies looking to de-risk combination product development and enhance patient experiences in chronic disease management.

Ypsomed AG

Ypsomed AG is a premier Swiss developer and manufacturer of self-injection systems, offering an extensive platform-based portfolio that includes the YpsoMate autoinjector series, pen injectors, and wearable patch injectors. With a strong focus on modularity and sustainability, the company’s YpsoLoop circular solution highlights its commitment to eco-friendly design without compromising patient convenience. Ypsomed’s “Clear to Clinic” program further supports its pharmaceutical partners by providing clinic-ready devices that accelerate clinical development and shorten time-to-market for innovative subcutaneously administered therapies.

SHL Medical AG

SHL Medical AG is a world-leading solutions provider specializing in the design, development, and manufacturing of advanced self-injection systems, most notably the Molly family of modular autoinjectors. As a vertically integrated company, SHL offers end-to-end services from initial design and tooling to final assembly and packaging across three continents. Its focus on large-volume and high-viscosity delivery, supported by proprietary technologies like Rotaject and Needle Isolation Technology (NIT), positions SHL as a dominant player in the rapidly growing cardiometabolic and chronic disease sectors.

West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a global leader in innovative solutions for injectable drug administration, providing critical components and delivery systems like the SmartDose electronic wearable injector and the SelfDose patient-controlled injector. The company specializes in primary container-device integration, ensuring compatibility between complex biologics and delivery hardware to improve safety and efficacy. West’s extensive technical expertise and global regulatory support enable pharmaceutical partners to navigate the complexities of combination product commercialization while enhancing patient adherence.

Owen Mumford Ltd.

Owen Mumford Ltd. is a major British medical device manufacturer known for its pioneer work in self-injection and capillary blood sampling, offering a wide range of autoinjectors under the Aidaptus and Autoject brands. The company focuses on user-centric design, providing platforms that accommodate various syringe sizes and fill volumes with minimal customization. Owen Mumford’s commitment to innovation and manufacturing excellence supports the delivery of therapies for diabetes, multiple sclerosis, and other chronic conditions in both clinical and home care settings.

Phillips-Medisize, LLC

Phillips-Medisize, LLC, a Molex company, is a leading global contract development and manufacturing organization (CDMO) that specializes in complex drug delivery devices, including connected autoinjectors and electronic injectors. By leveraging its deep expertise in human factors engineering and electronics integration, the company provides end-to-end solutions from early-stage design to high-volume commercial production. Phillips-Medisize is a key enabler for digital health initiatives, helping pharmaceutical companies develop smart injection systems that track adherence and improve patient outcomes.

Halozyme, Inc.

Halozyme, Inc. is a biopharmaceutical company primarily known for its ENHANZE drug delivery technology, which utilizes a recombinant human hyaluronidase enzyme (rHuPH20) to facilitate the subcutaneous delivery of large-volume injectable drugs. This technology allows for the rapid administration of complex biologics that would otherwise require long intravenous infusions, often enabling the use of autoinjectors for home-based care. Halozyme partners with leading global pharmaceutical companies to reformulate existing therapies, significantly improving patient convenience and treatment flexibility.

AbbVie Inc.

AbbVie Inc. is a research-driven global biopharmaceutical company that utilizes advanced autoinjector technology to deliver its market-leading therapies for immunology, oncology, and neuroscience. The company has successfully integrated patient-friendly self-injection devices, such as the Humira Pen, into its product life cycle to enhance patient independence and compliance. AbbVie’s focus on specialty medicine development is supported by continuous investment in drug delivery innovation, ensuring that its complex biologics are accessible and easy for patients to administer outside of clinical settings.

Amgen Inc.

Amgen Inc. is a biotechnology pioneer that leverages sophisticated drug delivery systems, including the SureClick autoinjector platform and Pushtronex wearable injectors, to provide life-changing therapies for cardiovascular disease, oncology, and inflammation. The company’s “Biology First” approach extends to its delivery technologies, ensuring that its large-molecule biologics are delivered accurately and safely. Amgen’s commitment to patient-centric innovation is reflected in its efforts to simplify the administration of high-frequency and large-volume medications, improving the overall treatment experience.

Eli Lilly and Company

Eli Lilly and Company is a global healthcare leader with a dominant presence in the diabetes and obesity markets, where it utilizes proprietary autoinjector and pen platforms for therapies like Mounjaro and Zepbound. The company focuses on developing intuitive, easy-to-use delivery devices that reduce the burden of frequent injections for patients managing chronic conditions. Lilly’s integrated approach to drug and device development, combined with its large-scale manufacturing capabilities, ensures the reliable supply of advanced subcutaneous therapies to a rapidly growing global patient base.

Novo Nordisk A/S

Novo Nordisk A/S is a global leader in diabetes and obesity care, renowned for its extensive portfolio of prefilled pen injectors and autoinjectors, including the FlexPen and FlexTouch platforms. The company specializes in the high-volume production of reliable, precise delivery systems for insulin and GLP-1 therapies, emphasizing patient ease of use and dose accuracy. Novo Nordisk’s strategic focus on innovation includes the development of connected “smart” pens and sustainable delivery solutions, reinforcing its commitment to long-term chronic disease management and environmental responsibility.

Johnson & Johnson Services Inc.

Johnson & Johnson Services Inc., through its Innovative Medicine division, provides a diverse range of injectable therapies for immunology and oncology, supported by advanced self-injection technologies. The company utilizes various autoinjector platforms to deliver specialty medications, focusing on improving patient adherence and clinical outcomes through ergonomic and reliable device designs. J&J’s global reach and vertically integrated capabilities allow it to effectively manage the entire lifecycle of drug-device combination products, from early-stage research to large-scale global distribution.

Sanofi

Sanofi is a leading global healthcare company that offers a broad spectrum of injectable medications for diabetes, rare diseases, and immunology, often delivered via user-friendly autoinjector and pen devices like the SoloStar. The company is committed to transforming the treatment landscape by integrating digital health solutions with its delivery platforms to support better disease management. Sanofi’s focus on patient-centric design ensures that its therapies are convenient for self-administration, helping to maintain high levels of adherence across its extensive portfolio of chronic care treatments.

GSK plc

GSK plc is a global biopharma company that utilizes advanced autoinjector systems to deliver specialty medicines for respiratory diseases, lupus, and oncology. The company’s focus on “Getting Ahead of Disease Together” is supported by its investment in delivery technologies that simplify the administration of complex biologics, such as the Nucala autoinjector. GSK’s commitment to innovation and patient access drives its efforts to develop robust, reliable self-injection solutions that empower patients to manage their conditions effectively in a home setting.

AstraZeneca

AstraZeneca is a science-led biopharmaceutical company that leverages innovative autoinjector technology to deliver its portfolio of biologics for oncology, cardiovascular, and respiratory conditions. The company utilizes delivery platforms like the Bydureon BCise to provide once-weekly subcutaneous treatments, focusing on simplifying complex dosing regimens for patients. AstraZeneca’s strategic emphasis on personalized medicine and digital health integration aims to enhance the patient experience by providing smarter, more convenient ways to administer life-saving medications.

Gerresheimer AG

Gerresheimer AG is a leading global partner to the pharma and biotech industries, providing a wide range of specialty glass and plastic products, including the Gx InnoSafe and specialized primary packaging for autoinjectors. The company offers integrated solutions that combine high-quality primary containers with drug delivery device components, ensuring optimal compatibility and safety. Gerresheimer’s focus on innovation in containment and delivery systems supports its customers in bringing complex injectable therapies to market efficiently and securely.

Haselmeier GmbH

Haselmeier GmbH, part of the Medadom Group, is a specialist in the development and manufacture of innovative self-injection systems, including the D-Flex and Axis-D pen injector platforms. The company provides customized delivery solutions for pharmaceutical partners, focusing on high-precision mechanical designs that improve patient safety and ease of use. Haselmeier’s expertise in pen and autoinjector technology, combined with its flexible manufacturing capabilities, makes it a preferred partner for companies seeking tailored delivery systems for specialty medications.

Oval Medical Technologies Ltd.

Oval Medical Technologies Ltd., a subsidiary of SMC Ltd., is a specialist medical device company focused on the design of next-generation autoinjectors that can handle highly viscous and large-volume biologics. Its proprietary platform technology utilizes a unique internal architecture that eliminates the need for a traditional spring-driven mechanism, allowing for greater control and reliability. Oval’s focus on “patient-centricity” drives its development of compact, easy-to-use devices that address the technical challenges of delivering modern specialty drugs.

Kaleo, Inc.

Kaleo, Inc. is a pharmaceutical company that specializes in developing innovative delivery systems for life-saving medications, most notably the AUVI-Q epinephrine auto-injector. The company’s platforms are characterized by their compact design and unique features, such as voice instructions, which are intended to reduce user error during medical emergencies. Kaleo’s “patient-driven” innovation model focuses on redesigning existing drug-device combinations to make them more intuitive and reliable for both patients and caregivers in high-stakes situations.

Solteam Incorporation Co., Ltd.

Solteam Incorporation Co., Ltd. is an emerging manufacturer of medical components and drug delivery devices, providing specialized solutions for the autoinjector and pen injector markets. The company focuses on high-precision injection molding and automated assembly to produce cost-effective, high-quality components for pharmaceutical partners. Solteam’s commitment to technical excellence and manufacturing scalability supports the global supply chain for self-injection systems, particularly in the rapidly expanding Asian healthcare markets.

Elcam Drug Delivery Devices (E3D)

Elcam Drug Delivery Devices (E3D) is a specialized division of Elcam Medical that focuses on the design and manufacture of innovative autoinjectors and mechanical delivery platforms. The company offers the Flexi-Q series of autoinjectors, which are designed to accommodate both glass and plastic prefilled syringes with minimal modification. E3D’s focus on providing versatile, high-performance delivery systems helps pharmaceutical companies accelerate their product development timelines while ensuring a high level of patient comfort and safety.

Crossject

Crossject is a specialty pharmaceutical company known for developing ZENEO, a needle-free, single-use auto-injection system. This innovative technology uses a high-pressure gas propellant to deliver medication through the skin in less than a tenth of a second, offering a significant alternative for patients with needle phobia or those in emergency situations. Crossject is focusing on the commercialization of ZENEO for various indications, including epilepsy and anaphylaxis, aiming to provide a faster, safer, and more intuitive delivery method than traditional needle-based injectors.

Jabil, Inc.

Jabil, Inc. is a massive global manufacturing solutions provider that offers comprehensive CDMO services for the healthcare sector, including the development and large-scale production of electronic and connected autoinjectors. Through its Jabil Healthcare division, the company combines deep expertise in electronics, materials science, and high-volume automation to help pharmaceutical companies bring smart delivery devices to market. Jabil’s global footprint and sophisticated supply chain capabilities make it a vital partner for the industrialization of complex, next-generation drug delivery technologies.

Congruence Medical Solutions LLC

Congruence Medical Solutions LLC is a specialized drug delivery company that focuses on solving the challenges associated with delivering difficult-to-inject formulations, such as highly viscous drugs and ultra-low volumes. The company offers innovative platforms like the Microneedle Delivery System and specialized autoinjectors designed for precise subcutaneous and ophthalmic administration. Congruence’s engineering-driven approach helps pharmaceutical partners optimize the delivery of niche and specialty therapies that require unique containment and injection profiles.

Midas Pharma GmbH

Midas Pharma GmbH is a global pharmaceutical services company that provides end-to-end solutions for the development and supply of drug-device combination products, including autoinjectors. The company acts as a strategic partner, offering services that range from active pharmaceutical ingredient (API) sourcing and formulation development to the selection and integration of delivery devices. Midas Pharma’s comprehensive project management and regulatory expertise enable its clients to navigate the entire value chain, ensuring the successful market entry of complex injectable medications.

Download PDF Brochure:“Click Here”